| 1. |
- Nilsson, Magnus, et al.
(author)
-
Measuring tolerance towards self-harm: Introducing the Lund Tolerance Towards Self-Harm Scale (LUTOSH).
- 2019
-
In: Stigma and health. - : American Psychological Association (APA). - 2376-6972 .- 2376-6964. ; 5:3, s. 315-322
-
Journal article (peer-reviewed)abstract
- Although self-harm is a common behavior and exists in many contexts, previous research on tolerance and attitudes has focused primarily on health care providers. Less is known about tolerance toward self-harm in the general population. To the best of our knowledge, there is currently no scale assessing public tolerance toward self-harm. For this purpose, a brief scale was constructed and tested for its psychometric properties in 2 samples: a general population sample (n = 336) and a sample of staff working in mental health care (n = 582). A 5-item version of this scale was found to have acceptable internal consistency and was labeled the Lund Tolerance Toward Self-Harm Scale (LUTOSH). Principal components analysis and confirmatory factor analysis indicated a 2-factor structure, with subscales that were named Tolerance and Intolerance. Convergent validity was established by analyzing correlations assessing attitudes toward other aspects of mental health and attitudes toward self-harm among psychiatric nurses. Research exploring the sensitivity to change over time of the measure is needed to further evaluate to usefulness of LUTOSH. In conclusion, results indicate that LUTOSH can be used as a brief instrument to explore public, and possibly provider, tolerance toward self-harm.
|
|
| 2. |
- San Segundo-Acosta, Pablo, et al.
(author)
-
Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers
- 2021
-
In: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 20:11, s. 5115-5130
-
Journal article (peer-reviewed)abstract
- New biomarkers of Alzheimer's disease (AD) with a diagnostic value in preclinical and prodromal stages are urgently needed. AD-related serum autoantibodies are potential candidate biomarkers. Here, we aimed at identifying AD-related serum autoantibodies using protein microarrays and mass spectrometry-based methods. To this end, an untargeted complementary screening using high-density (42,100 antigens) and low-density (384 antigens) planar protein-epitope signature tag (PrEST) arrays and an immunoprecipitation protocol coupled to mass spectrometry analysis were used for serum autoantibody profiling. From the untargeted screening phase, 377 antigens corresponding to 338 proteins were selected for validation. Out of them, IVD, CYFIP1, and ADD2 seroreactivity was validated using 128 sera from AD patients and controls by PrEST-suspension bead arrays, and ELISA or luminescence Halotag-based bead immunoassay using full-length recombinant proteins. Importantly, IVD, CYFIP1, and ADD2 showed in combination a noticeable AD diagnostic ability. Moreover, IVD protein abundance in the prefrontal cortex was significantly two-fold higher in AD patients than in controls by western blot and immunohistochemistry, whereas CYFIP1 and ADD2 were significantly down-regulated in AD patients. The panel of AD-related autoantigens identified by a comprehensive multiomics approach may provide new insights of the disease and should help in the blood-based diagnosis of Alzheimer's disease. Mass spectrometry raw data are available in the ProteomeXchange database with the access number PXD028392.
|
|
